Ohio State Early Investor Network Disclaimer

OSEIN does not provide investment advice, and the information contained in this memo should not be solely relied upon for making investment decisions. Investors are encouraged to conduct their own due diligence and seek professional advice before making any investment. OSEIN does not assume any liability or responsibility for investment outcomes. Additionally, AI was used to review, synthesize, and prepare the following information.

Investing in early-stage and angel investments is inherently risky, and investors should be aware that they may lose their entire investment. By proceeding with any investment, investors acknowledge and assume these risks and understand that the outcomes can be unpredictable and may not result in financial gain.

Company: Jabez Biosciences

Website: https://www.jabezbio.com/

LinkedIn: linkedin.com/company/jabez-biosciences

Venture360 Deal Profile: https://ohiostateearlyinvestornetwork.venture360.co/companies/139367-jabez-biosciences/deals/30198

Pitch Deck

Ohio State Innovation Foundation Jabez Investment Memo (redacted)

Jabez Financial Forecast

Jabez Biosciences Pitch Session

Follow Up Questions

Basic Company Information

1. Company Name: Jabez Biosciences, Inc.
2. Date of Incorporation: May 22, 2024 (State of incorporation: Florida)
3. Business Overview: Clinical-stage biopharmaceutical oncology company developing JBZ-001, an orally bioavailable DHODH inhibitor for solid and hematologic cancers. The first patient was dosed in Phase I at OSUCCC–James, with additional site expansion in 2025. Jabez holds an exclusive license (effective July 16, 2024) from the Ohio State Innovation Foundation covering relevant DHODH intellectual property.
4. Overall Raise: Up to $10,000,000 via Regulation A+ (Tier 2) at $2.00/share (5,000,000 Class A shares; Tier 2 framework allows up to $75M in 12 months).
5. Form of Business Entity: C Corp